Top

Published in:

Open Access 01-02-2021 | Parkinson's Disease | Original Communication

Parkinson’s disease laterality: a ¹¹C-PE2I PET imaging study

Authors: Andreas-Antonios Roussakis, Zhou Zeng, Nicholas P. Lao-Kaim, Antonio Martin-Bastida, Paola Piccini, TRANSEURO consortium

Published in: Journal of Neurology | Issue 2/2021

Abstract

Asymmetry of striatal dopaminergic deficits and motor symptoms is a typical characteristic of idiopathic Parkinson’s disease (PD). This study aims to characterise the trend of asymmetry in moderate-stage PD. We performed a 19-month longitudinal study in 27 patients with PET-CT imaging and appropriate clinical assessments. ¹¹C-PE2I non-displaceable binding potential (BP_ND) was calculated bilaterally for the striatum at baseline and follow-up to estimate the in vivo density of striatal dopamine transporters (DAT). Changes in striatal ¹¹C-PE2I BP_ND over time were more prominent in the ipsilateral as compared to contralateral side. Changes in MDS-UPDRS-III (motor component of the Movement Disorders Society Unified PD Rating Scale) were not different between the clinically most and least affected body sides. Our data support that the asymmetry in striatal dopaminergic degeneration becomes less prominent in moderate-stage PD. In contrast, during the above period, the asymmetry of motor symptoms was maintained between the clinically most and least affected body sides.

Riederer P, Jellinger KA, Kolber P, Hipp G, Sian-Hülsmann J, Krüger R (2018) Lateralisation in Parkinson disease. Cell Tissue Res 373(1):297–312. https://doi.org/10.1007/s00441-018-2832-zCrossRefPubMed

Poewe W, Mahlknecht P (2012) Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson's disease. Expert Rev Neurother 12(8):911–914. https://doi.org/10.1586/ern.12.75CrossRefPubMed

Yust-Katz S, Tesler D, Treves TA, Melamed E, Djaldetti R (2008) Handedness as a predictor of side of onset of Parkinson's disease. Parkinsonism Relat Disord 14(8):633–635. https://doi.org/10.1016/j.parkreldis.2008.01.017CrossRefPubMed

Barrett MJ, Wylie SA, Harrison MB, Wooten GF (2011) Handedness and motor symptom asymmetry in Parkinson's disease. J Neurol Neurosurg Psychiatry 82(10):1122–1124. https://doi.org/10.1136/jnnp.2010.209783CrossRefPubMed

Shi J, Liu J, Qu Q (2014) Handedness and dominant side of symptoms in Parkinson's disease. Med Clin 142(4):141–144. https://doi.org/10.1016/j.medcli.2012.11.028CrossRef

Wiberg A, Ng M, Al Omran Y, Alfaro-Almagro F, McCarthy P, Marchini J, Bennett DL, Smith S, Douaud G, Furniss D (2019) Handedness, language areas and neuropsychiatric diseases: insights from brain imaging and genetics. Brain. https://doi.org/10.1093/brain/awz257CrossRefPubMedPubMedCentral

Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, Lee CS, McKenzie J, McCormick S, Samii A, Troiano A, Ruth TJ, Sossi V, de la Fuente-Fernandez R, Calne DB, Stoessl AJ (2009) Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 132(11):2970–2979. https://doi.org/10.1093/brain/awp209%JBrainCrossRefPubMed

Yagi S, Yoshikawa E, Futatsubashi M, Yokokura M, Yoshihara Y, Torizuka T, Ouchi Y (2010) Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET. J Nucl Med 51(8):1250–1257. https://doi.org/10.2967/jnumed.110.076802CrossRefPubMed

Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K (2018) Longitudinal change of clinical and biological measures in early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. Mov Disord 33(5):771–782. https://doi.org/10.1002/mds.27361CrossRefPubMedPubMedCentral

10.

Miller-Patterson C, Buesa R, McLaughlin N, Jones R, Akbar U, Friedman JH (2018) Motor asymmetry over time in Parkinson’s disease. J Neurol Sci 393:14–17. https://doi.org/10.1016/j.jns.2018.08.001CrossRefPubMed

11.

Lee CS, Schulzer M, Mak E, Hammerstad JP, Calne S, Calne DB (1995) Patterns of asymmetry do not change over the course of idiopathic Parkinsonism. Neurology 45(3):435. https://doi.org/10.1212/WNL.45.3.435CrossRefPubMed

12.

Li W, Lao-Kaim NP, Roussakis AA, Martin-Bastida A, Valle-Guzman N, Paul G, Loane C, Widner H, Politis M, Foltynie T, Barker RA, Piccini P (2018) (11) C-PE2I and (18) F-Dopa PET for assessing progression rate in Parkinson's: a longitudinal study. Mov Disord 33(1):117–127. https://doi.org/10.1002/mds.27183CrossRefPubMed

13.

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170. https://doi.org/10.1002/mds.22340CrossRefPubMed

14.

Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K, Initiative* tPsPM (2018) Longitudinal change of clinical and biological measures in early Parkinson's Disease: Parkinson's progression markers initiative cohort. Mov Disord: Official J Mov Disord Soc 33(5):771–782. https://doi.org/10.1002/mds.27361CrossRef

15.

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184. https://doi.org/10.1136/jnnp.55.3.181CrossRefPubMedPubMedCentral

16.

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25(15):2649–2653. https://doi.org/10.1002/mds.23429CrossRefPubMed

17.

Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19(9):1020–1028. https://doi.org/10.1002/mds.20213CrossRefPubMed

18.

Plotnik M, Giladi N, Balash Y, Peretz C, Hausdorff JM (2005) Is freezing of gait in Parkinson's disease related to asymmetric motor function? Ann Neurol 57(5):656–663. https://doi.org/10.1002/ana.20452CrossRefPubMed

19.

Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM (2012) FSL NeuroImage 62(2):782–790. https://doi.org/10.1016/j.neuroimage.2011.09.015CrossRefPubMed

20.

Hall H, Halldin C, Guilloteau D, Chalon S, Emond P, Besnard J, Farde L, Sedvall G (1999) Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I. NeuroImage 9(1):108–116CrossRef

21.

Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, Lundkvist C, Olsson H, Guilloteau D, Emond P, Farde L (2003) [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 30(9):1220–1230. https://doi.org/10.1007/s00259-003-1212-3CrossRefPubMed

22.

Jucaite A, Odano I, Olsson H, Pauli S, Halldin C, Farde L (2006) Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging 33(6):657–668. https://doi.org/10.1007/s00259-005-0027-9CrossRefPubMed

23.

Li W, Lao-Kaim NP, Roussakis AA, Martín-Bastida A, Valle-Guzman N, Paul G, Loane C, Widner H, Politis M, Foltynie T, Barker RA, Piccini P (2018) 11C-PE2I and 18F-Dopa PET for assessing progression rate in Parkinson's: a longitudinal study. Mov Disord: Official J Mov Disor Soc 33(1):117–127. https://doi.org/10.1002/mds.27183CrossRef

24.

Brooks DJ (2010) Imaging dopamine transporters in Parkinson's disease. Biomark Med 4(5):651–660. https://doi.org/10.2217/bmm.10.86CrossRefPubMed

25.

Sossi V, Dinelle K, Jivan S, Fischer K, Holden JE, Doudet D (2012) In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of Parkinson disease using 11C-methylphenidate PET. J Nucl Med 53(5):813–822. https://doi.org/10.2967/jnumed.111.101436CrossRefPubMed

26.

Marinus J, van Hilten JJ (2015) The significance of motor (a)symmetry in Parkinson's disease. Mov Disord 30(3):379–385. https://doi.org/10.1002/mds.26107CrossRefPubMed

27.

Uitti RJ, Baba Y, Whaley NR, Wszolek ZK, Putzke JD (2005) Parkinson disease: Handedness predicts asymmetry. Neurology 64(11):1925–1930. https://doi.org/10.1212/01.WNL.0000163993.82388.C8CrossRefPubMed

28.

Reinoso G, Allen JC Jr, Au W-L, Seah S-H, Tay K-Y, Tan LCS (2015) Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study. Eur J Neurol 22(3):457–463. https://doi.org/10.1111/ene.12476CrossRefPubMed

29.

Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE (2007) Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22(16):2409–2417. https://doi.org/10.1002/mds.21743CrossRefPubMed

30.

López IC, Ruiz PJ, Del Pozo SV, Bernardos VS (2010) Motor complications in Parkinson's disease: ten year follow-up study. Mov Disord 25(16):2735–2739. https://doi.org/10.1002/mds.23219CrossRefPubMed

31.

Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J, McCormick S, Ruth TJ, Sossi V, de la Fuente-Fernandez R, Stoessl AJ (2011) Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 134(Pt 11):3290–3298. https://doi.org/10.1093/brain/awr233CrossRefPubMed

32.

Tedroff J, Ekesbo A, Rydin E, Långström B, Hagberg G (1999) Regulation of dopaminergic activity in early Parkinson's disease. Ann Neurol 46(3):359–365. https://doi.org/10.1002/1531-8249(199909)46:3<359:Aid-ana11>3.0.Co;2-gCrossRefPubMed

33.

Oaks AW, Marsh-Armstrong N, Jones JM, Credle JJ, Sidhu A (2013) Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking. PLoS ONE 8(8):e70872. https://doi.org/10.1371/journal.pone.0070872CrossRefPubMedPubMedCentral

34.

Nikolaus S, Antke C, Hautzel H, Mueller HW (2016) Pharmacological treatment with L-DOPA may reduce striatal dopamine transporter binding in in vivo imaging studies. Nuklearmedizin Nucl Med 55(1):21–28. https://doi.org/10.3413/Nukmed-0764-15-08CrossRef

35.

Kuramoto L, Cragg J, Nandhagopal R, Mak E, Sossi V, de la Fuente-Fernández R, Stoessl AJ, Schulzer M (2013) The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling. PLoS ONE 8(10):e76595. https://doi.org/10.1371/journal.pone.0076595CrossRefPubMedPubMedCentral

36.

van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, Innis RB (2002) Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 10(1):36–43CrossRef

Title: Parkinson’s disease laterality: a 11C-PE2I PET imaging study
Authors: Andreas-Antonios Roussakis
Zhou Zeng
Nicholas P. Lao-Kaim
Antonio Martin-Bastida
Paola Piccini
TRANSEURO consortium
Publication date: 01-02-2021
Publisher: Springer Berlin Heidelberg
Keywords: Parkinson's Disease
Movement Disorder
Published in: Journal of Neurology / Issue 2/2021
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-10204-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Parkinson’s disease laterality: a ¹¹C-PE2I PET imaging study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis

Liliana Lubińska (1904–1990)

Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature

Towards early disease modification of Parkinson’s disease: a review of lessons learned in the Alzheimer field

Isolated post SARS‑CoV‑2 diplopia

Dangerous sweets: severe hypokalemia with rhabdomyolysis and tetraparesis from chronic consumption of licorice